C1071032: A Phase 3, Open-Label Study of Elranatamab Monotherapy versus Elotuzumab, Pomalidomide, Dexamethasone (EPd) or Pomalidomide, Brotezomib, Dexamethasone 9PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed/Refractory Multiple Myeloma who Received Prior Anti-CD38 Directed Therapy
- Title
- A Phase 3, Open-Label Study of Elranatamab Monotherapy versus Elotuzumab, Pomalidomide, Dexamethasone (EPd) or Pomalidomide, Brotezomib, Dexamethasone 9PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed/Refractory Multiple Myeloma who Received Prior Anti-CD38 Directed Therapy
- Principal Investigator
- Safi, Salah Ud Din
- Phase
- III
- Age Group
- Adult
- Applicable Disease Sites
- Multiple Myeloma
- Participating Institutions
- Mary Babb Randolph Cancer Center
- Contacts
- Kathryn Oliverio, LPN
- Research Specialist
- Phone: +1 304-293-7374
- Email: kathryn.oliverio1@hsc.wvu.edu